Friday, November 28, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Wall Street Analysts Boost Price Targets for Xometry Following Strong Quarterly Results

Felix Baarz by Felix Baarz
August 28, 2025
in Stocks
0
Xometry Stock
0
SHARES
307
VIEWS
Share on FacebookShare on Twitter

The digital manufacturing marketplace Xometry continues to garner a “Moderate Buy” consensus rating from Wall Street analysts. This assessment is supported by nine research firms, with six recommending a ‘Buy’ and three maintaining a ‘Neutral’ stance. The collective average price target for the stock stands at $40.44.

Impressive Q2 2025 Performance Drives Optimism

The recent wave of analyst upgrades is firmly rooted in the company’s exceptional second-quarter financial performance, which handily surpassed market expectations. Xometry reported a significant year-over-year revenue increase of 22.6%, achieving a total of $162.55 million against an anticipated $156.53 million. Earnings per share also outperformed, coming in at $0.09 compared to the $0.05 forecast. A key profitability metric, Adjusted EBITDA, showed a substantial improvement of $6.6 million year-over-year to reach a positive $3.9 million. Reflecting this strong momentum, the stock hit a 52-week high of $48.64 on August 22, representing a remarkable 143.44% gain over the past twelve months.

A Series of Upward Revisions

This robust operational performance has triggered a succession of positive adjustments from financial institutions, indicating a widespread reassessment of Xometry’s growth potential. The flurry of activity began in early August:

Should investors sell immediately? Or is it worth buying Xometry?

  • Cantor Fitzgerald upgraded its rating from “Underweight” to “Neutral” on August 5, simultaneously establishing a $41 price target.
  • On August 6, UBS raised its target from $35 to $40, though it maintained a “Neutral” recommendation.
  • Also on August 6, JMP Securities issued a more bullish revision, increasing its price objective from $45 to $50 and reaffirming its “Market Outperform” rating.
  • Earlier, on June 3, JPMorgan had increased its target from $36 to $38, maintaining an “Overweight” position on the stock.

Record Quarterly Revenue Fuels Growth

The core driver behind this analyst enthusiasm is the platform’s exceptional operational performance. Xometry’s marketplace segment was the primary growth engine, expanding by 26% and propelling the company to a record Q2 revenue of $163 million. This figure marks a 23% increase compared to the same period last year. This top-line strength flowed through to profitability, with Gross Profit also climbing by 23% to reach $65.2 million.

Institutional Confidence Contrasts with Insider Sales

An examination of the shareholder base reveals a fascinating dynamic. Institutional investors demonstrate overwhelming confidence, holding a commanding 97.31% of all shares. Recent filings show that firms including GAMMA Investing LLC and SG Americas Securities have significantly increased their stakes, a move interpreted as a strong endorsement of the company’s long-term strategy.

This makes a contrasting action by CEO Randolph Altschuler in early July particularly noteworthy. During this period, he sold shares valued at over $302,000. While insider selling can attract scrutiny, the continued and growing dominance of large institutional investors presents a powerful counter-narrative of belief in Xometry’s future.

Ad

Xometry Stock: Buy or Sell?! New Xometry Analysis from November 28 delivers the answer:

The latest Xometry figures speak for themselves: Urgent action needed for Xometry investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 28.

Xometry: Buy or sell? Read more here...

Tags: Xometry
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Suzano Stock

Suzano's Strategic Shift Yields Impressive Financial Turnaround

Intuitive Surgical Stock

Intuitive Surgical's Workforce Reduction Sparks Investor Concern

Palantir Stock

Palantir's Market Rollercoaster: Valuation Concerns Clash With Record Performance

Recommended

Finance_Commercial

Coinbase Global Announces 11 Billion Convertible Senior Notes Offering

2 years ago
American Express Stock

American Express Doubles Down on Premium Strategy with Card Revamp and Partnerships

2 months ago
Realty Income Stock

Realty Income’s Strategic Expansion Tests Dividend Legacy

3 months ago
Healthcare Services Stock Exchange

Revolutionizing Melanoma Diagnosis DermTechs Groundbreaking Findings

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

CureVac Shareholders Face Final Deadline in BioNTech Takeover

Voestalpine Shares Surge on Ukrainian Infrastructure Contract

Metaplanet’s Bold Bitcoin Strategy Fuels Spectacular Rally

Aventis Energy Secures Permits for Long-Awaited Corvo Uranium Exploration

Ballard Power Shares: Signs of a Turnaround?

Bitcoin’s Rebound: A Sustainable Recovery or Bull Trap?

Trending

Atlassian Stock
Analysis

Atlassian Leadership Continues Aggressive Stock Disposal Amid Strong Performance

by Dieter Jaworski
November 28, 2025
0

While Atlassian shares gained nearly 2% to reach $150.86 on Friday, recent SEC filings reveal a concerning...

Novo Nordisk Stock

Is Novo Nordisk’s Stock Decline a Buying Opportunity?

November 28, 2025
Barrick Stock

Barrick Gold Executes Major Strategic Moves with Billion-Dollar Mine Sale and African Resolution

November 28, 2025
CureVac Stock

CureVac Shareholders Face Final Deadline in BioNTech Takeover

November 28, 2025
Voestalpine Stock

Voestalpine Shares Surge on Ukrainian Infrastructure Contract

November 28, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Atlassian Leadership Continues Aggressive Stock Disposal Amid Strong Performance
  • Is Novo Nordisk’s Stock Decline a Buying Opportunity?
  • Barrick Gold Executes Major Strategic Moves with Billion-Dollar Mine Sale and African Resolution

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com